It’s been a good week for investors of Pyxis Oncology (NASDAQ:PYXS), to say the least. Over the past 4 sessions Pyxis shares have gained 170%, bringing the year-to-date haul to a mighty 340%. This ...
Pyxis Group and Principia Consulting today announced the formation of a strategic joint venture to jointly serve the global ...
BOSTON, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced a leadership ...
Pyxis Oncology needs to pave a longer cash runway. To do so, the Pfizer-partnered antibody-drug conjugate (ADC) biotech is cutting 40% of staff, slimming its programs and looking to monetize royalty ...
Pyxis Oncology is slimming down after a tough start to life on public markets, pausing work on two assets and stopping development of a third altogether to focus its cash on getting its lead programs ...
Welcome to Indie App Spotlight. This is a weekly 9to5Mac series where we showcase the latest apps in the indie app world. If you’re a developer and would like your app featured, get in contact. Pyxis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results